JP2010529999A5 - - Google Patents

Download PDF

Info

Publication number
JP2010529999A5
JP2010529999A5 JP2010512385A JP2010512385A JP2010529999A5 JP 2010529999 A5 JP2010529999 A5 JP 2010529999A5 JP 2010512385 A JP2010512385 A JP 2010512385A JP 2010512385 A JP2010512385 A JP 2010512385A JP 2010529999 A5 JP2010529999 A5 JP 2010529999A5
Authority
JP
Japan
Prior art keywords
composition
polysorbate
phosphate buffer
sodium chloride
sodium phosphate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010512385A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010529999A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/066928 external-priority patent/WO2008157356A2/en
Publication of JP2010529999A publication Critical patent/JP2010529999A/ja
Publication of JP2010529999A5 publication Critical patent/JP2010529999A5/ja
Pending legal-status Critical Current

Links

JP2010512385A 2007-06-14 2008-06-13 抗体製剤 Pending JP2010529999A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94407607P 2007-06-14 2007-06-14
PCT/US2008/066928 WO2008157356A2 (en) 2007-06-14 2008-06-13 Antibody formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013182749A Division JP2014040424A (ja) 2007-06-14 2013-09-04 抗体製剤

Publications (2)

Publication Number Publication Date
JP2010529999A JP2010529999A (ja) 2010-09-02
JP2010529999A5 true JP2010529999A5 (enExample) 2011-07-28

Family

ID=39956053

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010512385A Pending JP2010529999A (ja) 2007-06-14 2008-06-13 抗体製剤
JP2013182749A Pending JP2014040424A (ja) 2007-06-14 2013-09-04 抗体製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013182749A Pending JP2014040424A (ja) 2007-06-14 2013-09-04 抗体製剤

Country Status (24)

Country Link
US (3) US20080311119A1 (enExample)
EP (2) EP2170390B1 (enExample)
JP (2) JP2010529999A (enExample)
CN (2) CN103977404A (enExample)
AR (2) AR067011A1 (enExample)
AU (1) AU2008266051B2 (enExample)
BR (1) BRPI0814252B8 (enExample)
CA (1) CA2690382A1 (enExample)
CY (1) CY1121208T1 (enExample)
DK (1) DK2170390T3 (enExample)
EA (1) EA020456B1 (enExample)
ES (1) ES2707815T3 (enExample)
HR (1) HRP20182146T1 (enExample)
HU (1) HUE041555T2 (enExample)
IL (1) IL202648B (enExample)
LT (1) LT2170390T (enExample)
MX (2) MX2009013593A (enExample)
NZ (2) NZ595526A (enExample)
PL (1) PL2170390T3 (enExample)
PT (1) PT2170390T (enExample)
SI (1) SI2170390T1 (enExample)
TR (1) TR201820837T4 (enExample)
TW (1) TWI614028B (enExample)
WO (1) WO2008157356A2 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3777880A1 (en) 2003-02-10 2021-02-17 Biogen MA Inc. Immunoglobulin formulation and method of preparation thereof
EP2453874A2 (en) * 2009-07-14 2012-05-23 Biogen Idec MA Inc. Methods for inhibiting yellow color and peroxide formation in a composition
CA2789061A1 (en) 2010-02-26 2011-09-01 Henrik Parshad Stable antibody containing compositions
LT3345615T (lt) 2010-03-01 2020-02-10 Bayer Healthcare Llc Optimizuoti monokloniniai antikūnai prieš audinių faktoriaus kelio slopiklį (tfpi)
PT3202789T (pt) 2010-04-16 2020-06-16 Biogen Ma Inc Anticorpos anti-vla-4
RS66182B1 (sr) 2010-05-28 2024-12-31 Novo Nordisk As Stabilne višedozne kompozicije koje sadrže antitelo i konzervans
WO2013006461A1 (en) * 2011-07-01 2013-01-10 Biogen Idec Ma Inc. Cholesterol-based media supplementals for cell culture
US10485869B2 (en) 2011-10-18 2019-11-26 Coherus Biosciences, Inc. Etanercept formulations stabilized with meglumine
AR088381A1 (es) 2011-10-18 2014-05-28 Coherus Biosciences Inc Formulaciones de etanercept estabilizadas con meglumina
WO2013123114A2 (en) * 2012-02-16 2013-08-22 Santarus, Inc. Antibody formulations
CN104520326A (zh) * 2012-06-21 2015-04-15 Ucb医药有限公司 药物制剂
IN2015KN00005A (enExample) 2012-07-09 2015-07-31 Coherus Biosciences Inc
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
MX360044B (es) 2012-09-11 2018-10-19 Coherus Biosciences Inc Etanercept plegado correctamente con alta pureza y un rendimiento excelente.
CN103217525B (zh) * 2013-03-21 2015-04-29 上海执诚生物科技股份有限公司 一种含有提高胱抑素c胶乳包被抗体的稳定性的组合物、稳定剂及其制备方法和用途
WO2015063180A1 (en) * 2013-10-29 2015-05-07 Novozymes Biopharma Dk A/S Antibody composition
KR102362002B1 (ko) * 2013-11-29 2022-02-10 제넨테크, 인크. 항체 선택 장치 및 방법
CA2938933A1 (en) 2014-03-12 2015-09-17 Prothena Biosciences Limited Anti-laminin4 antibodies specific for lg4-5
JP2017510627A (ja) * 2014-03-13 2017-04-13 プロセナ バイオサイエンシーズ リミテッド 多発性硬化症の併用治療
BR112016028182A2 (pt) * 2014-06-02 2018-02-20 Lab Francais Du Fractionnement método para produzir um fragmento de fragmento cristalizável, e, fragmento fc.
MX2017004975A (es) * 2014-10-18 2017-06-30 Pfizer Composiciones de anticuerpos anti-il-7r.
MX2018014560A (es) 2016-05-27 2019-08-12 Alexion Pharma Inc Metodos para el tratamiento de la miastenia gravis generalizada refractaria.
GB201612317D0 (en) 2016-07-15 2016-08-31 Philogen Spa Antibody compositions
GB201703062D0 (en) * 2017-02-24 2017-04-12 Arecor Ltd Stabilized antibody protein solutions
US11608357B2 (en) 2018-08-28 2023-03-21 Arecor Limited Stabilized antibody protein solutions
EP3372242A1 (en) 2017-03-06 2018-09-12 Ares Trading S.A. Liquid pharmaceutical composition
EP3372241A1 (en) 2017-03-06 2018-09-12 Ares Trading S.A. Liquid pharmaceutical composition
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
CN110913906A (zh) 2017-05-02 2020-03-24 默沙东公司 抗lag3抗体的制剂和抗lag3抗体与抗pd-1抗体的共制剂
CA3080187A1 (en) 2017-10-26 2019-05-02 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) and atypical hemolytic uremic syndrome (ahus)
CN112292146A (zh) * 2018-04-10 2021-01-29 雷迪博士实验室有限公司 治疗性抗体的稳定的制剂
WO2019236417A1 (en) 2018-06-04 2019-12-12 Biogen Ma Inc. Anti-vla-4 antibodies having reduced effector function
US12312394B2 (en) 2018-06-28 2025-05-27 Alexion Pharmaceuticals, Inc. Methods of producing anti-C5 antibodies
CN113316458B (zh) 2018-11-07 2024-08-02 默沙东有限责任公司 抗lag3抗体和抗pd-1抗体的共制剂
WO2021007504A2 (en) * 2019-07-10 2021-01-14 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising reduced level of host cell proteins
EP4021497A4 (en) * 2019-08-30 2023-09-06 Kashiv Biosciences, LLC NOVEL FORMULATION OF A HIGHLY CONCENTRATED PHARMACOLOGICALLY ACTIVE ANTIBODIES
CN113134081A (zh) * 2020-01-20 2021-07-20 上海君实生物医药科技股份有限公司 抗btla抗体药物组合物及其用途
JPWO2022092183A1 (enExample) * 2020-10-30 2022-05-05
KR20230107644A (ko) 2020-11-14 2023-07-17 바이오젠 엠에이 인코포레이티드 항-vla-4 항체에 대한 2상 피하 투여 요법
EP4323407A1 (en) 2021-04-13 2024-02-21 Biogen MA Inc. Compositions and methods for treating chronic active white matter lesions / radiologically isolated syndrome

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) * 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) * 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4475196A (en) * 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) * 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
JPS62196921A (ja) 1986-02-25 1987-08-31 Nec Corp 位相検出回路
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) * 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5312335A (en) * 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
US5383851A (en) * 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
RU2185393C2 (ru) 1993-01-06 2002-07-20 Кинертон Лимитед Сложный полиэфир и конъюгат на его основе
NZ261259A (en) 1993-01-12 1996-12-20 Biogen Inc Humanised recombinant anti-vla4 antibody and diagnostic compositions and medicaments
AU687790B2 (en) * 1993-02-09 1998-03-05 Biogen Idec Ma Inc. Treatment for insulin dependent diabetes
US5827690A (en) * 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
DK0804237T3 (da) * 1994-01-25 2006-10-16 Elan Pharm Inc Humaniserede antistoffer mod leukocyt-adhæsionsmolekyle VLA-4
US5840299A (en) * 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
DE19541844C1 (de) 1995-11-09 1997-07-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung
CN103275221B (zh) 1996-02-09 2016-08-17 艾伯维生物技术有限公司 结合人TNFα的人抗体
DE69738539T2 (de) 1996-12-03 2009-03-26 Amgen Fremont Inc. Vollkommen humane Antikörper die EGFR binden
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
WO2001055112A1 (en) 2000-01-27 2001-08-02 American Cyanamid Company Method for preparing alpha-sulfonyl hydroxamic acid derivatives
US8288322B2 (en) 2000-04-17 2012-10-16 Dyax Corp. Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
EP3777880A1 (en) * 2003-02-10 2021-02-17 Biogen MA Inc. Immunoglobulin formulation and method of preparation thereof
CA2478458A1 (en) 2004-08-20 2006-02-20 Michael Panzara Treatment of pediatric multiple sclerosis
EP1827491A4 (en) * 2004-11-19 2010-07-14 Biogen Idec Inc TREATMENT OF MULTIPLE SCLEROSIS
WO2008021954A2 (en) 2006-08-09 2008-02-21 Biogen Idec Ma Inc. Method for distribution of a drug

Similar Documents

Publication Publication Date Title
JP2010529999A5 (enExample)
JP2010522208A5 (enExample)
JP2011088913A5 (enExample)
NZ595526A (en) Pharmaceutical composition comprising a vla-4 binding antibody, a phosphate buffer and a surfactant
IL215275A0 (en) Pharmaceutical formulations and methods for treating respiratory tract infections
MX352949B (es) Composicion farmaceutica.
JP2012184234A5 (enExample)
HRP20161577T1 (hr) Inhibitori replikacije virusa gripe
JP2009531457A5 (enExample)
UA115648C2 (uk) Доставка терапевтичних агентів до цнс
JP2015527402A5 (enExample)
HRP20110414T1 (hr) Indoli i njihova uporaba u liječenju
CL2012001966A1 (es) Formulación farmacéutica que comprende entre 100-150 mg/ml de un anticuerpo que se une específicamente al receptor a de il-17 humana, una solución acuosa de un buffer 5-30 mm de ácido glutámico ph 4,5-5,2, prolina 2-4% p/v y polisorbato-20 0,005-0,02% p/v; envase farmacéutico y kit que comprende dicha formulación; y su uso para tratar psoriasis.
HRP20150744T4 (hr) Modulatori farmakokinetičkih svojstava lijekova
MY166045A (en) Abeta antibody formulation
NZ597237A (en) Sublingual apomorphine
JP2012255026A5 (enExample)
RU2009126767A (ru) Производное 1-фенил-1-тио-d-глюцитола
NO20082904L (no) Feksofenadinsupensjonsformulering
JP2013508315A5 (enExample)
PE20110943A1 (es) Formulacion oral solida de alisquireno
CY1112917T1 (el) Υγρες στοματικες συνθεσεις
JP2005527551A5 (enExample)
JP2016510747A5 (enExample)
TR201001417A1 (tr) Geliştirilmiş çözünme hızına sahip sefdinir formülasyonu